Does the regional use of intensive chemotherapy impact the outcome of adults with AML? by Corentin Orvain

Get full text

Measurable residual disease as predictor of post–day +100 relapses after allografting in adult AML by Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Corentin Orvain, Filippo Milano, Brenda M. Sandmaier, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter

Get full text

Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02) by Sarah Bertoli, Emilie Bérard, Pierre Peterlin, Romain Guieze, Yohan Desbrosses, Yosr Hicheri, Omar Benbrahim, Martin Carre, Corentin Orvain, Anne Banos, Marc Bernard, Emmanuel Gyan, Alain Saad, Safia Chebrek, Gabrielle Roth Guepin, Veronique Dorvaux, Laurence Sanhes, Maria Pilar Gallego-Hernanz, Carole Exbrayat, Laure Vincent, Chantal Himberlin, Célestine Simand, Norbert Vey, Cindy Fenoll, Ariane Mineur, Anne Huynh, Francois Vergez, Isabelle Luquet, Laetitia Largeaud, Eric Delabesse, Arnaud Pigneux, Christian Récher, French Innovative Leukemia Organization FILO

Get full text